MFAP5

Chr 12AD

microfibril associated protein 5

Also known as: AAT9, MAGP-2, MAGP2, MFAP-5, MP25

The protein is a microfibril-associated glycoprotein that serves as a component of elastin-associated microfibrils in the extracellular matrix and promotes cell attachment via alpha-V-beta-3 integrin. Mutations cause familial thoracic aortic aneurysm with autosomal dominant inheritance. The gene shows tolerance to loss-of-function variants (low constraint), suggesting the cardiovascular phenotype may involve specific functional disruption rather than simple protein loss.

Summary from RefSeq, OMIM, UniProt
Research Assistant →

Primary Disease Associations & Inheritance

Aortic aneurysm, familial thoracic 9MIM #616166
AD
0
Active trials
25
Pubs (1 yr)
41
P/LP submissions
0%
P/LP missense
0.85
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryMFAP5
🧬
Gene-Disease Validity (ClinGen)
familial thoracic aortic aneurysm and aortic dissection · ADModerate

Moderate evidence — consider for supplementary testing

Population Constraint (gnomAD)
Low constraint (pLI 0.01) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
40 unique Pathogenic / Likely Pathogenic· 158 VUS of 373 total submissions
📖
GeneReview available — MFAP5
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.85LOEUF
pLI 0.005
Z-score 1.97
OE 0.43 (0.230.85)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.32Z-score
OE missense 0.91 (0.771.08)
96 obs / 105.3 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.43 (0.230.85)
00.351.4
Missense OE0.91 (0.771.08)
00.61.4
Synonymous OE1.13
01.21.6
LoF obs/exp: 6 / 14.0Missense obs/exp: 96 / 105.3Syn Z: -0.60
DN
0.7131th %ile
GOF
0.5367th %ile
LOF
0.2678th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
LOF1 literature citation

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

LOFAnalysis of patient fibroblasts demonstrated pure haploinsufficiency, and transfection studies confirmed that the R158X mutation abrogates protein production.PMID:25434006

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

373 submitted variants in ClinVar

Classification Summary

Pathogenic36
Likely Pathogenic4
VUS158
Likely Benign109
Benign40
Conflicting18
36
Pathogenic
4
Likely Pathogenic
158
VUS
109
Likely Benign
40
Benign
18
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
1
0
35
0
36
Likely Pathogenic
2
0
2
0
4
VUS
16
111
29
2
158
Likely Benign
0
4
59
46
109
Benign
0
0
40
0
40
Conflicting
18
Total1911516548365

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

MFAP5 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →